metabolic
CagriSema
Amylin + GLP-1 combination research stack
0 vendors tracked0 live pricesLast crawl: warming up
About
A combination of cagrilintide and semaglutide in late-stage clinical development for obesity. Research-compound version mirrors the clinical dose ratio.
Also known as: Cagrilintide + Semaglutide combination, GLP-1 (S) + Cagrilintide, GLP-1 (S) + Cagrilintide Blend, Sema + Cagri Blend, Sema+Cagri
Reconstitution calculator
!
For research purposes only. Not for human consumption. Always verify calculations independently.
Cost-per-dose recalculates as you adjust the calculator above.
Research use only. The compounds listed on this page are not approved for human use through research-chemical channels. Nothing on this page is medical advice. Consult a qualified clinician before considering any peptide protocol. See affiliate disclosure and our scoring methodology.
Keep exploring
More on CagriSema & related research
Related peptides
- Cagrilintide— Amylin analog for weight research
- Semaglutide— GLP-1 agonist for metabolic research
- Tirzepatide— Dual GLP-1/GIP agonist
- Retatrutide— Triple GCG/GIP/GLP-1 agonist
- Mazdutide— GLP-1/glucagon dual agonist
Compare head-to-head